secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001171843-23-001254
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q4 net loss $26.5M ($0.56/sh); barzolvolimab Phase 2 CSU enrollment to complete by Q3 2023
--------------------------------------------------------------------------------

- Net loss of $26.5M ($0.56 per share) for Q4 2022; full year net loss $112.3M ($2.40 per share).
- Cash, cash equivalents and marketable securities at Dec 31, 2022: $305.0M, down from $323.5M at Sep 30, 2022.
- Revenue $1.6M in Q4 2022, $2.4M for full year; R&D expenses $22.9M in Q4, $82.3M for full year.
- Barzolvolimab Phase 2 CSU enrollment expected to complete by Q3 2023; topline data late 2023 or Q1 2024.
- Rita Jain, M.D. appointed to Board of Directors; Phase 2 EoE study initiation expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/0001171843-23-001254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/f8k_022823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer